# China NMPA Product Recall - Far-infrared muscle and bone activating patch

Source: https://www.globalkeysolutions.net/records/china_product_recall/anhui-jingdao-biotechnology-co-ltd/d968c694-eb36-49df-8b37-a96a25fd33d9/
Source feed: China

> China NMPA product recall for Far-infrared muscle and bone activating patch by Anhui Jingdao Biotechnology Co., Ltd. published February 10, 2022. Recall level: Level 3 Recall. Anhui Jinyang Biotechnology Co., Ltd. initiated a voluntary Class III recall of its "Far-Infrared Mu

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Anhui Jinyang Biotechnology Co., Ltd. voluntarily recalls
- Company Name: Anhui Jingdao Biotechnology Co., Ltd.
- Publication Date: 2022-02-10
- Product Name: Far-infrared muscle and bone activating patch
- Recall Level: Level 3 Recall
- Recall Reason: Product may have quality issues.
- Discovering Company: Anhui Jinyang Biotechnology Co., Ltd.
- Manufacturing Company: Anhui Jingdao Biotechnology Co., Ltd.
- Summary: Anhui Jinyang Biotechnology Co., Ltd. initiated a voluntary Class III recall of its "Far-Infrared Muscle and Bone Activating Patch" (Registration/Filing No.: "皖械注淮202020") due to identified potential quality issues. This recall was officially reported on February 10, 2022, as indicated by the National Medical Products Administration (NMPA) and the Anhui Provincial Drug Administration. The decision for a voluntary recall was made by Anhui Jinyang Biotechnology Co., Ltd. to address concerns regarding the quality of the medical device. While specific details of the quality issues are not provided in this public notice, the company has documented these in a "Medical Device Recall Event Report Form" which includes information on affected models, specifications, and batches. The NMPA, the central regulatory authority for medical products in China, and its provincial counterpart, the Anhui Provincial Drug Administration, are overseeing this action. A Level III recall signifies that the product's use is unlikely to cause adverse health consequences. This action demonstrates the company's commitment to product safety and compliance with the regulatory framework set forth by the NMPA, ensuring public health protection. The recall process requires the company to systematically remove the affected products from the market and notify relevant parties, aligning with established medical device recall protocols.

Company: https://www.globalkeysolutions.net/companies/anhui-jingdao-biotechnology-co-ltd/c55db187-37c3-4d8d-8da8-7eafd07396ff/